Skip to content

Innoviva, Inc. INVA Preferred Stock

Preferred Stock at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$0
LQD
Liquidia CorporationLQDA
$0
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$0
United Therapeutics logo
United TherapeuticsUTHR
$0
Zymeworks logo
ZymeworksZYME
$0
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$0

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Innoviva, Inc.'s preferred stock?
Innoviva, Inc. (INVA) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.